Clinical presentation, progression, and management of five cases of Ross River virus infection in performance horses located in Southeast Queensland: a longitudinal case series by Barton, Anita Jane & Bielefeldt-Ohmann, Helle
Accepted Manuscript
Clinical presentation, progression and management of 5 cases of Ross River virus
infection in performance horses located in southeast Queensland: A longitudinal case
series
A.J. Barton, H. Bielefeldt-Ohmann
PII: S0737-0806(16)30505-6
DOI: 10.1016/j.jevs.2016.12.010
Reference: YJEVS 2236
To appear in: Journal of Equine Veterinary Science
Received Date: 18 August 2016
Revised Date: 21 December 2016
Accepted Date: 23 December 2016
Please cite this article as: Barton A, Bielefeldt-Ohmann H, Clinical presentation, progression and
management of 5 cases of Ross River virus infection in performance horses located in southeast
Queensland: A longitudinal case series, Journal of Equine Veterinary Science (2017), doi: 10.1016/
j.jevs.2016.12.010.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 1 of 19 
Clinical presentation, progression and 1 
management of 5 cases of Ross River virus 2 
infection in performance horses located in 3 
southeast Queensland: A longitudinal case 4 
series 5 
 6 
by AJ Bartona* and H Bielefeldt-Ohmanna,b 7 
aSchool of Veterinary Science, The University of Queensland, Gatton, QLD 4343, Australia 8 
bAustralian Infectious Diseases Research Centre, University of Queensland, St. Lucia, QLD 4078, Australia 9 
 10 
*Corresponding author email: a.scampton@uq.edu.au 11 
 * Corresponding author address: Building 8114, University of Queensland Gatton Campus, Gatton 4343, 12 
Australia 13 
 14 
Word count: 4500 15 
Keywords 16 
Ross River virus; horse; arbovirus; arthritis; febrile illness; lethargy 17 
 18 
Authorship: A.B collected retrospective clinic data and prepared the manuscript. H.B.O 19 
analysed serological samples and edited the manuscript. 20 
 21 
 22 
 23 
 24 
 25 
 26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 2 of 19 
 27 
 28 
 29 
Abstract 30 
Background: Ross River virus (RRV), a mosquito-transmitted alphavirus prevalent in 31 
Australia, is believed to cause poor performance, lethargy and muscle stiffness in Australian 32 
horses. However, disease progression and management is poorly documented. A better 33 
understanding of disease presentation, acute therapy and long-term management is 34 
required. 35 
Objectives: To describe clinical presentation, diagnosis, acute treatment and long term 36 
management of RRV-infection in horses 37 
Study design: Retrospective case series 38 
Methods: Clinical and diagnostic data were obtained from both veterinary records and 39 
owner interviews for 5 performance horses that presented with acute poor performance 40 
coupled with serological evidence of RRV exposure. Clinical and owner reports were 41 
evaluated from the time of presentation until the horses appeared asymptomatic and had 42 
returned to normal performance. 43 
Results: RRV was suspected to be the cause of generalized muscle stiffness and poor 44 
performance in 5 performance horses located in southeast Queensland between 2011 and 45 
2015. Clinical symptoms included pyrexia, tachypnoea, exercise intolerance, generalized 46 
muscle stiffness, synovial effusion, and oedema of the lower limbs. Serological investigations 47 
(ELISA and/or virus neutralization assay) detected antibody responses to RRV. Horses were 48 
treated with non-steroidal anti-inflammatory drugs (n=5) and disease-modifying 49 
osteoarthritis drugs (n=2). Most horses returned to previous athletic capabilities between 7 50 
and 12 months after onset of symptoms.  51 
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Main limitations: Not all horses in the study had pre-clinical serology or submitted paired 52 
blood samples for serology, meaning assumption of acute infection in those horses was 53 
made based on clinical signs coupled with positive serology 54 
Conclusion: RRV is a significant but poorly understood cause of poor performance in 55 
Australian horses. This report is the only one to document longitudinal management of 56 
performance horses affected by RRV infection. Much more research is needed to gain a 57 
better understanding of this infection in horses. 58 
 59 
Abbreviations 60 
AID, Australian Infectious Diseases Research Center; AST, aspartate aminotransferase; BFV, 61 
Barmah Forest virus; CHIKV, Chikungunya virus; CK, creatinine kinase; DMOAD, disease-62 
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Encephalitis virus; KUNV, kunjin virus; MAYV, Mayaro virus; MVEV, Murray Valley 64 
Encephalitis virus; NSAID, non-steroidal anti-inflammatory drugs; ONNV, O’nyong-nyong 65 
virus; RT-PCR, real-time polymerase chain reaction; RRF, Ross River fever; RRV, Ross River 66 
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neutralising antibody titre 68 
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Introduction 78 
Ross River virus (RRV) is an arthropod-borne Alphavirus in the family Togaviridae found in 79 
Australia and Papua New Guinea, and is suspected to occur epidemically in the Solomon 80 
Islands [1; 2]. The primary vertebrate reservoir host for RRV may vary regionally and 81 
seasonally, but includes possums, macropods, such as kangaroos and wallabies, and humans 82 
[3-5]. Although birds commonly feature as reservoir hosts for many other arboviruses, RRV 83 
antibody prevalence in birds is generally low, and avian species are generally not considered 84 
important in transmission of RRV [4]. The major arthropod vector for RRV is believed to be 85 
Aedes vigilax in coastal regions of northern and eastern Australia, Aedes camptorhynchus in 86 
southern and southwestern Australia, and Culex annulirostris in tropical and temperate 87 
inland areas, although the virus has been isolated from over 30 different species of mosquito 88 
Australia-wide [6]. Even though serological surveys have detected RRV-specific antibodies in 89 
a range of wild and domestic species, such as marsupials, livestock and domestic pets, it is 90 
unknown if animals other than marsupials play a role in amplification and transmission of 91 
the virus, or if RRV is capable of causing symptomatic disease in animal species other than 92 
horses and humans [2; 7; 8]. Speculation exists about whether horses function as a reservoir 93 
host for RRV, and if they play a role in disease transmission to humans. It appears that in 94 
most cases viraemia is transient in horses and humans, and they are generally unable to 95 
amplify the virus sufficiently to extend transmission to mosquitoes. Nevertheless, some 96 
evidence exists that in unique circumstances human viraemia may be high enough to 97 
perpetuate the transmission cycle, and it is possible this could occur in horses also [3; 4; 9; 98 
10]. A recent documented case of transfusion-transmission of RRV has also proven that, in 99 
exceptional circumstances, human to human transmission of the virus is possible [11]. 100 
 101 
RRV is responsible for debilitating illness in both humans and horses characterised by severe 102 
arthralgia, myalgia, fever and fatigue and known as ‘epidemic polyarthritis’ or Ross River 103 
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fever. Clinical disease in humans presents as severe joint pain and lethargy, in some cases 104 
preceded by a transient fever (~30% of cases), and may be accompanied by a transient rash 105 
[2; 12]. Arthritis and arthralgia typically affect the knees, ankles, wrists and small joints in the 106 
fingers. Fatigue and arthralgia in humans has been reported to persist for as long as six to 107 
twelve months [12-14]. Relapses of clinical signs following periods of illness or stress have 108 
been suspected but not definitively documented.  109 
 110 
Very few studies document the effects of RRV infection in horses [15; 16], despite it being 111 
suspected of causing poor performance and musculoskeletal disease in the Australian 112 
equine population for more than 25 years [17; 18]. Reports to date suggest horses 113 
experience a transient fever and often present acutely with non-specific viral vasculitis of 114 
hind or fore limbs resulting in 'filling' or oedema of the limb between the fetlock and carpus 115 
or hock. Swelling of joints, ataxia, submandibular lymphadenopathy, oral petechiae and high 116 
serum fibrinogen and globulin levels have also been reported [15; 16]. 117 
 118 
This case series documents clinical presentation and progression during 12 or more months 119 
in 5 performance horses located in southeast Queensland and suspected of having RRV-120 
induced disease. Diagnosis was made based on clinical symptoms coupled with  121 
seroconversion to the virus. Cases were presented between 2011 and 2015. Four of the five 122 
horses were located within the Lockyer Valley region. 123 
 124 
Case reports 125 
Table 1.  126 
Insert Table 1 127 
 128 
Case study 1 129 
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A 6-year-old warmblood gelding dressage horse located in the Lockyer Valley, Southeast 130 
Queensland, presented in February 2011 for acute onset inappetence, depression, marked 131 
reluctance to move and stiffness in his gait at walk. Rectal temperature was 40.0°C. The 132 
owner reported no limb swelling at this time. Hematology examination revealed mild 133 
neutropenia (N-), anaemia (An) and lymphocytosis (Ly+). Serological test for RRV 6 weeks 134 
later revealed elevated IgM (1:20480) and IgG (1:20480) in ELISA performed at IDEXX 135 
Laboratories, Brisbane. The horse was treated acutely with non-steroidal anti-inflammatory 136 
drugs (NSAIDs) (Phenylbutazone 3mg/kg initially, followed by 2mg/kg orally BID for 10 days). 137 
Temperature and appetite returned to normal within 24 hours of commencing NSAIDs. The 138 
horse was rested in paddock and the owner reported an obvious stiffness to gait and on 139 
flexion of limbs for about 2 months after first presenting, with a gradual improvement over 140 
the following month. Three months after presenting the horse was placed into light exercise, 141 
but was reported to remain subtly stiff through his limbs, and was spelled in the paddock for 142 
a further 3 months. At this time the horse returned to training with apparent resolution of 143 
all clinical signs. 144 
 145 
As the owner was satisfied of the diagnosis, a follow-up blood test to monitor changes in 146 
RRV antibody levels was not made. 147 
 148 
Case study 2 149 
A 12-year-old Clydesdale gelding dressage horse located in the Lockyer Valley, Southeast 150 
Queensland, presented in May 2012 with a history of transient low-grade pyrexia (39.4°C 151 
recorded on one occasion), oedema of both hindlimbs from the fetlock to hock of less than 152 
24hrs duration, and persistent synovial effusion of the hind fetlocks that lasted 4 months. 153 
The horse was treated acutely with NSAIDs (Phenylbutazone 3mg/kg initially, followed by 154 
2mg/kg orally BID for 5 days) and given two weeks’ rest from exercise. On returning to 155 
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exercise the rider observed the horse to have a slight exercise intolerance characterized by 156 
an inability to sustain activity, increased sweating and a delayed recovery in respiratory rate. 157 
Blood was collected at this point and tested for routine hematology and biochemistry and 158 
arbovirus isolation. Hematology and biochemistry results were unremarkable. An ELISA 159 
screening for RRV, performed at the Australian Infectious Diseases Research Center (AID), 160 
University of Queensland, was negative. A virus-neutralising antibody test, also performed at 161 
the AID using the RRV prototype strain T48 [19-21] gave a titre of 1:320 for RRV  and was 162 
negative for Murray Valley Encephalitis virus (MVEV) and Kunjin virus (KUNV). Samples taken 163 
from this horse 7 months prior to illness as part of a research survey had returned a negative 164 
virus-neutralizing titre (VNT) to RRV [20]. The horse was rested for 6 months in the paddock 165 
and treated with the disease-modifying osteoarthritis drug (DMOAD) pentosan polysulphate 166 
3mg/kg IM monthly. Seven months after initial presentation the horse returned to training 167 
with apparent resolution of exercise intolerance. Follow-up samples taken 3 years later and 168 
submitted to the AID as part of continued arbovirus surveillance reported a VNT of >1:2880.  169 
 170 
Case study 3 171 
An 8-year-old warmblood stallion dressage horse located in East Brisbane, Southeast 172 
Queensland, presented in February 2013 with a history of exercise intolerance and dyspnoea 173 
during exercise. The horse developed anhydrosis and displayed a markedly increased 174 
respiratory rate, around 100bpm, for up to 3 hours following exercise. The owner reported 175 
swelling of the hind limbs from fetlock to hock of 7 days’ duration that did not go down 176 
following exercise or icing. The horse became progressively inappetant and continued to 177 
show tachypnoea even once he was placed on stable rest. At no time did the owner detect 178 
an elevation in rectal temperature. On clinical exam, the horse was depressed, moderately 179 
dehydrated and had an elevated respiratory rate (45bpm). Clinical examination and thoracic 180 
auscultation were unremarkable. The stallion was admitted for endoscopic examination, 181 
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blood and urine tests and placed on IV fluids. No abnormalities were detected on 182 
endoscopic examination or urinalysis. Plasma biochemistry showed an increase above 183 
normal reference range in creatinine kinase (CK) (621u/l; normal 113-375u/l) and aspartate 184 
aminotransferase (AST) (463u/l; normal 194-440u/l), both indicators of muscular damage. 185 
Hematology was unremarkable. An ELISA test performed at IDEXX Laboratories, Brisbane for 186 
RRV revealed an elevated IgM (1:20480) and IgG (1:20480). A paired sample was not 187 
submitted. The stallion was treated with NSAIDs (Phenylbutazone 3mg/kg initially, followed 188 
by 2mg/kg orally BID for 21 days), an iron supplement and sodium acid citrate 7.93g SID to 189 
aid in muscle damage repair. He was rested from exercise for three months and hand walked 190 
twice daily during this time. He then commenced a month of short walks under saddle, 191 
followed by a further two months of gradual increase in workload. The owner reported the 192 
horse as still having exercise intolerance, anhydrosis and fatiguing quickly with exercise. The 193 
horse had a further six months of rest from exercise and a change in diet to reduce the levels 194 
of starch and sugar. The owner reported an improvement in both the anhydrosis and 195 
demeanor. Tachypnoea resolved one month after commencing the iron supplement. 196 
 197 
Case study 4 198 
A 10-year-old warmblood mare dressage horse located in the Lockyer Valley, Southeast 199 
Queensland, presented in February 2015 with 3-month history of neck stiffness to lateral 200 
bending during exercise, a low-grade intermittent cough both in the paddock and on 201 
commencement of exercise, and mild loss of performance characterized by lethargy and 202 
delayed response to rider’s aids during work. The owner had observed no joint swelling or 203 
oedema of the limbs. No pyretic episodes had been detected during the preceding 3 204 
months. The mare had been screened for RRV 24 months prior when an in-contact horse 205 
had been conclusively diagnosed with RRV, and her VNT at that time was zero. The mare was 206 
admitted for cervical radiographs and endoscopic examination of the upper airways. Blood 207 
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was collected for general hematology, biochemistry and VNT for RRV. Cervical radiographs 208 
detected no evidence of bone disease, and mild hyperemia of the pharyngeal region was 209 
observed on endoscopy. Routine hematology and biochemistry results were unremarkable. 210 
RRV-specific neutralization titre performed at the AID was 1:160. A follow-up VNT to the 211 
same laboratory 2 months later was 1:2880. The mare was treated with rest, a short course 212 
of NSAIDs (phenylbutazone 2mg/kg orally BID for 5 days), and a combination of DMOADs 213 
(Pentosan polysulphate 3mg/kg IM fortnightly and hyaluronic acid 60mg IV weekly for 5 214 
weeks). Two months after presenting to the clinician the mare returned to training and the 215 
owner reported an improvement in all clinical signs except for an intermittent cough at the 216 
beginning of each training session. The cough appeared to resolve after 3 months back into 217 
work (9 months after the suspected date of virus infection). The owner also felt the mare 218 
seemed to have increased susceptibility to respiratory infections following attendance at 219 
organised performance events, which resulted in a temporary relapse in stiffness and 220 
lethargy. Periods of ‘relapse’ lasted around 2 weeks in each instance (4 episodes over a 6 221 
months’ period), accompanied by a mild increase in rectal temperature. The owner also 222 
reported some low-grade intermittent irregularity in gait, when the horse was asked to trot 223 
on a firm surface, that had not been present prior to contracting RRV infection. The reason 224 
for the irregularity remained undiagnosed and appeared to improve with anti-concussive 225 
corrective shoeing. 226 
 227 
Case study 5 228 
A 10-year-old warmblood gelding dressage horse located in the Lockyer Valley, Southeast 229 
Queensland presented in March 2015 with acute onset of intermittent low-grade lameness 230 
on commencement of exercise, neck stiffness to lateral bending during exercise, a loss of 231 
performance characterized by reluctance to work, reduced responsiveness to riders’ aids 232 
and rapid fatigue, and an elevated respiratory rate at rest. The owner reported enlarged 233 
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fetlocks and generalized malaise in the paddock. A month after onset of clinical signs the 234 
owner observed laminar rings on the proximal hoof capsule that had not been there 235 
previously. No evidence of distal phalangeal rotation was observed radiographically. An 236 
initial serum sample was taken 6 weeks after the onset of clinical signs. A paired sample was 237 
taken four weeks later. Both samples were submitted for serology. The initial RRV-specific 238 
neutralization titre was 1/1440, the follow-up VNT one month later was 1:2880. The horse 239 
was treated with rest and NSAIDs (phenylbutazone 2mg/kg orally BID for 5 days). Ten 240 
months after initial presentation the horse returned to training with mild residual stiffness. 241 
The owner reported an improvement in stiffness 12 months after initial clinical signs. 242 
 243 
Discussion 244 
RRV is an arthritogenic mosquito-borne disease endemic to Australia that is known to cause 245 
clinical disease in horses and humans, however, very little is known about the disease in 246 
horses.  247 
Clinical signs 248 
The clinical symptoms observed in the documented horses were consistent with previously 249 
reported cases [15; 16]. The consistent findings among all the cases were poor performance 250 
and generalized muscle stiffness. However, poor performance reports can be very non-251 
specific ranging from exercise intolerance and reluctance to work, stiffness to lateral 252 
bending exercises, to severe resistance and complete unwillingness to perform their regular 253 
work. Many other symptoms, such as pyrexia and oedema of limbs were reported by the 254 
owners to be transient, and may often be missed, precluding early detection of infection. It 255 
is likely that many cases of RRV in horses are overlooked due to owners blaming the 256 
symptoms on behavioral anomalies or training-related setbacks rather than suspecting viral 257 
disease. Some researchers still debate whether the virus is responsible for clinical disease in 258 
horses, due to limited published investigations, low reporting of clinical disease despite high 259 
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serological surveillance rates [9, 10, 14, 35], and poor understanding of the disease process 260 
in horses, but front-line astute veterinarians often correlate acute muscle stiffness and 261 
reluctance to perform in horses undertaking athletic pursuits with seroconversion to RRV.   262 
 263 
Serological surveillance of horses often detects prevalence rates of RRV as high as 65% [16; 264 
22]. Between 2010 and 2013 the Victorian Arbovirus Disease Program (VADCP), Agribio, 265 
Bundoora, recorded an incidence rate of approximately 30% in commercial samples from 266 
suspect horses submitted for arbovirus investigation, increasing to around 45% between 267 
2013 and 2015. It is difficult to obtain similar data from Queensland and New South Wales, 268 
as these states primarily test for Flavivirus and do not routinely check for RRV as is done in 269 
Victoria. However, a limited survey of horses entering race meetings in Brisbane in late 2012 270 
and early 2013 found that 20/70 (28%) and 22/47 (47%), respectively, were seropositive for 271 
RRV in a highly specific virus neutralization assays (Bielefeldt-Ohmann, Prow, Wright & Hall, 272 
unpublished data). Additional testing in the Summer of 2015-16 also revealed RRV-273 
neutralizing antibodies in ~50% or racehorses and horses admitted to the University of 274 
Queensland Equine Hospital for non-arthritic morbidities (Bielefeldt-Ohmann & Wiseman, 275 
unpublished data). Blood samples evaluated for routine hematology and biochemistry in 276 
horses with seroconversion to RRV often show no abnormalities, making screening for 277 
changes in inflammatory markers suggestive of a viral infection (neutrophilia/neutropenia, 278 
lymphocytosis, monocytosis) unreliable as a precursor to deciding whether or not to 279 
investigate for RRV. Infection must be suspected based primarily on clinical examination, 280 
and a decision to perform serology must be made independent of other laboratory 281 
investigation, as demonstrated in this case series.  282 
 283 
Management of RRV in horses and humans 284 
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Currently, there are no specific treatments, such as antivirals, or commercially available 285 
vaccines for alphavirus infection. There are also no reported clinical trials for therapeutic 286 
management of horses or humans affected by RRV. Surveillance of human patients affected 287 
by RRV found that one half of affected people surveyed reported pain relief to be the most 288 
effective management of joint pain (36.4% reported NSAIDs provided the most relief, while 289 
16.4% reported aspirin or paracetamol as providing the most effective relief) [14]. Rest was 290 
cited by 24.1% of human patients as their main source of relief. One study also reported a 291 
reduction in duration of clinical signs in human patients receiving corticosteroids [23], but to 292 
date all recommendations for therapeutic management of RRF in humans are based on 293 
subjective and anecdotal responses. Management of horses affected by RRV should include 294 
NSAIDs in the acute stages to control pyrexia, arthalgia and myalgia, and an extended period 295 
of rest from imposed exercise, such as ridden activities. The minimum anecdotal 296 
recommendation for rest based on duration of clinical symptoms in humans is 4 to 6 297 
months, and certainly in this investigation we observed most horses did not return to 298 
normal performance until between 7 and 12 months after onset of clinical symptoms. 299 
Chondroprotective agents, such as sodium hyaluronan or polysulphated glycosaminoglycans, 300 
may be of assistance in reducing arthralgia and arthritis [24; 25]. Responses from human 301 
surveys also indicate alternative therapies such as hydrotherapy and massage may provide 302 
relief to clinical symptoms,[14] and the use of these therapies could be adopted in the 303 
management of clinically affected horses. The potential for low-grade laminitis due to either 304 
pyrexia or systemic cytokine release [26; 27] should not be ruled out, and horses affected by 305 
RRV should be closely monitored during acute illness and convalescence for signs of pain 306 
within the hoof capsule. 307 
 308 
Diagnostic testing for RRV 309 
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Diagnosis of RRV is commonly made based on serological testing for IgM (acute phase) and 310 
IgG antibodies. Paired serum samples taken 2 to 4 weeks apart assist in making a more 311 
accurate diagnosis of recent infection. An IgM response is generally detectable 7 to 10 days 312 
after infection and peaks within 2 to 3 weeks before declining as antibody class switching 313 
occurs and IgG becomes the predominant antibody detected. Since IgG antibodies to RRV 314 
are believed to be life-long, detection of IgG in horses or humans can only demonstrate prior 315 
exposure to RRV. Certainly in this investigation, a very high antibody titre was detected in a 316 
horse 3 years after his initial infection. The detection of IgM, either alone or in combination 317 
with IgG enables an estimate of the time of infection. However, it should be noted that 1% 318 
of horses may maintain a detectable IgM titre for at least 18 months [15]. Diagnosis of a 319 
recent infection depends on showing an IgG seroconversion or a rising IgG titre. Where IgM 320 
is detected in the absence of IgG it is important to demonstrate IgG seroconversion on a 321 
convalescent sample. Cross reactivity with serological testing is documented and false 322 
positives have been reported with EIA IgM tests. Virus isolation can be performed using 323 
inoculation of tissue cultures or reverse transcription-polymerase chain reaction (RT-PCR). 324 
RT-PCR for viral RNA  (i.e., nucleic material) is a very specific and sensitive tool for diagnosing 325 
current/recent infection, and has been validated for use on equine blood and synovial fluid 326 
[28]. VNT are commonly used in research as they are more specific, but require PC2 327 
laboratory certification for handling of live virus and are time consuming. Cross reactivity 328 
with related alphaviruses and low neutralizing titres can affect this approach to diagnosis. 329 
 330 
Conclusion 331 
RRV is an arthritogenic mosquito-borne disease endemic to Australia that is known to cause 332 
clinical disease in horses and humans, however, very little is known about the disease in 333 
horses. Serological surveillance have detected infection rates as high as 65% in horses [16; 334 
22]. Clinical symptoms in horses are non-specific, and include exercise intolerance, joint 335 
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swelling, vascultis and oedema of the lower limbs, generalized musculoskeletal stiffness and 336 
transient pyrexia. It is likely that many cases are overlooked due to owners blaming the 337 
symptoms on behavioral anomalies or training-related setbacks rather than suspecting viral 338 
disease. Diagnosis of RRV in horses is best achieved by submitting paired serum samples 2 to 339 
4 weeks apart to a diagnostic laboratory and demonstration of either an isotype switch from 340 
virus-specific IgM to IgG antibodies, or a rising IgG titre. IgM antibodies may persist for as 341 
long as 18 months in the horse.[15] Recommendations on treatment for RRV are not based 342 
on clinical trials, but rather extrapolated from retrospective human surveillance and 343 
subjective feedback.  344 
 345 
The long-term sequelae of RRV infection in horses are not known. Horses are economically 346 
highly valuable animals, dependent on their athletic capabilities, and information regarding 347 
the inflammation and possible degradation of articular cartilage and subchondral bone is 348 
essential to provide information to trainers and riders about the crucial nature of 349 
appropriate rest and management of horses affected by RRV. More research is needed into 350 
clinical manifestations of RRV in horses, particularly the effects on joints, bone and hoof 351 
lamellae, as well as the affect of exercise on inflamed joints. Response of horses to 352 
treatment, such as NSAIDs or judicious use of corticosteroids, should also be assessed for 353 
any benefit in reducing severity of clinical signs or duration of illness. Given the considerable 354 
morbidity of this disease in both horses and humans, much more research needs to be 355 
conducted to provide a more evidence-based approach to therapeutics and management. 356 
 357 
This investigation is the only one to document clinical progression and management of RRV 358 
in horses over a longitudinal period. 359 
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 368 
Table 1. Summary of clinical findings and treatment in horses suspected to be infected with 369 
Ross River virus. N- = Neutrophilia; An = Anaemia; Ly+ = Lymphocytosis; CK = creatinine 370 
kinase; AST = Aspartate Aminotransferase 371 
 Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 
Pyrexia + + - - - 
Tachypnoea - + + - + 
Synovial effusion - + + - + 
Limb oedema - + + - - 
Muscle pain/stiffness + + + + + 
Lameness - - - + + 
Poor performance/lethargy + + + + + 
Inappetance/colic + - + - - 
Hematology changes N-, An, Ly+  - - - - 
Biochemistry changes - - CK +, AST + - - 
IgM titre      
   Sample 1 1:20480 - 1:20480 - - 
   Sample 2 - - - - - 
IgG titre      
   Sample 1 1:20480 - 1:20480 - - 
   Sample 2 - - - - - 
VNT      
   Sample 1 - 0 titre 7 
months prior 
to illness 
- 0 titre 2 
years prior 
to illness 
1:1440 
   Sample 2 - 1:320 - 1:160 1:2880 
   Sample 3 - >1:2880 - 1:2880 - 
Treatment      
   NSAID + + + + + 
   DMOAD - + - + - 
   Other - - Iron & 
sodium 
citrate 
- - 
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 372 
 373 
 374 
 375 
 376 
 377 
 378 
379 
Time to return to work 3 months 7 months 5 months 6 months 10 months 
Time to return to normal 
performance 
6 months 7 months 11 months 9 months 12 months 
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Highlights: 
 
• Ross River virus is an arthitogenic mosquito-borne Alphavirus endemic to 
Australia and Papua New Guinea 
• The virus causes debilitating disease in horses and humans known as 
Ross River Fever, characterised by joint pain, fatigue and fever that can 
last up to a year 
• Ross River fever in horses is poorly understood and often 
underdiagnosed 
• Management of Ross River Fever in horses and humans is symptomatic 
and based more on anecdotal reports rather than evidence-based 
medicine 
